Developing a Batch Isolation Procedure and Running It in an Automated Semicontinuous Unit: AWL CFD25 Case Study.
Journal
Organic process research & development
ISSN: 1083-6160
Titre abrégé: Org Process Res Dev
Pays: United States
ID NLM: 9890443
Informations de publication
Date de publication:
17 Apr 2020
17 Apr 2020
Historique:
received:
29
11
2019
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
28
4
2020
Statut:
ppublish
Résumé
A key challenge during the transition from laboratory/small batch to continuous manufacturing is the development of a process strategy that can easily be adopted for a larger batch/continuous process. Industrial practice is to develop the isolation strategy for a new drug/process in batch using the design of experiment (DoE) approach to determine the best isolation conditions and then transfer the isolation parameters selected to a large batch equipment/continuous isolation process. This stage requires a series of extra investigations to evaluate the effect of different equipment geometry or even the adaptation of the parameters selected to a different isolation mechanism (e.g., from dead end to cross flow filtration) with a consequent increase of R&D cost and time along with an increase in material consumption. The CFD25 is an isolation device used in the first instance to develop an isolation strategy in batch (optimization mode) using a screening DoE approach and to then verify the transferability of the strategy to a semicontinuous process (production mode). A d-optimal screening DoE was used to determine the effect of varying the input slurry. Properties such as solid loading, particle size distribution, and crystallization solvent were investigated to determine their impact on the filtration and washing performance and the characteristics of the dry isolated product. A series of crystallization (ethanol, isopropanol, and 3-methylbutan-1-ol) and wash solvents (
Identifiants
pubmed: 32336906
doi: 10.1021/acs.oprd.9b00512
pmc: PMC7171873
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
520-539Informations de copyright
Copyright © 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Int J Pharm. 2004 Feb 11;270(1-2):263-77
pubmed: 14726141
J Pharm Sci. 2019 Jan;108(1):372-381
pubmed: 30009797